VRDN logo

Viridian Therapeutics, Inc. Common Stock


VRDN: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.


Show VRDN Financials

Consumer Interest
SEC Filings

Recent trades of VRDN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by VRDN's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods for treatment of thyroid eye disease Jan. 10, 2023
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of VRDN in WallStreetBets Daily Discussion


Recent insights relating to VRDN

CNBC Recommendations

Recent picks made for VRDN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VRDN

Corporate Flights

Flights by private jets registered to VRDN